(RMD) ResMed Inc. Porters Five Forces Research

ResMed’s supplier power is moderate because some production steps rely on external contract manufacturers, so capacity tightness or tooling lock-in can raise costs. In FY2025, ResMed reported about $5.1 billion in revenue, and that scale plus global sourcing helps offset partner leverage. Still, if a key vendor is constrained, it can squeeze lead times and margins.

• External partners can gain leverage.
• Scale and sourcing reduce pressure.
• Overall supplier power stays moderate.

ResMed Inc.’s supplier switching friction stays high because parts changes can force design rework, re-testing, and new regulatory filings under FDA and ISO 13485 controls. In FY2025, ResMed generated about $5.1 billion in revenue, so even small sourcing delays can hit a large base. Long qualification cycles make short-term cost cuts hard, so supplier ties matter.

• Design lock-in raises switching costs
• Regulatory requalification slows moves
• Long ties support supply stability
• Buyer-side price pressure stays limited

Clinicians often stick with ResMed Inc. because the brand is tied to proven sleep apnea and respiratory care tools, plus patient adherence support. In FY2025, ResMed Inc. said revenue rose to about $5.1 billion, which shows strong demand and repeat use. That kind of trust cuts pure price switching, especially for mission-critical therapy.

So customer bargaining power stays moderate, not high, because brand reputation and clinical familiarity matter more than small price gaps.

• FY2025 revenue: about $5.1 billion
• Brand trust lowers price-only switching
• Clinician preference supports loyalty

ResMed’s customer power is moderate to high because patients rarely buy alone, but comfort and adherence still shape what distributors and care providers keep ordering. In FY2025, ResMed posted about $5.1 billion in revenue, and its recurring mask-and-device replacement flow means patient preference can quickly affect downstream demand.

• Patients drive adherence and brand choice.
• Providers balance comfort with cost control.
• Distributors can switch if demand slips.

ResMed's FY2025 revenue was about $5.1 billion, and that scale helps it compete in software as well as devices. In home care and post-acute care, rivals bundle billing, records, analytics, and workflow tools, so the fight is no longer just about masks and pumps. That pushes rivalry into recurring software revenue, which raises switching costs but also raises the stakes.

• Competes on bundled workflow software, not just devices.
• Recurring revenue makes rival platforms stickier.
• FY2025 revenue: about $5.1 billion.

ResMed serves about 140 countries, so rivals need scale, local compliance, and strong service in each market. In FY2025, ResMed posted about $5.1 billion in revenue, which shows the size of the battlefield. Global peers can pressure it in several regions at once, so broad reach plus category depth keeps rivalry high.

• 140-country reach raises the bar.
• FY2025 revenue: about $5.1B.
• Global rivals can attack on many fronts.

Digital coaching and telehealth can substitute for some of ResMed Inc.'s care workflow, especially in screening, adherence, and follow-up. In FY2025, ResMed Inc. reported revenue of about $5.1 billion, with masks and devices still the core therapy spend, so the substitution risk is more about shifting service dollars than replacing treatment itself.

• Higher threat in engagement
• Lower threat in core therapy
• Care spend can shift to apps
• Telehealth often complements devices

Pharmacological advances are a medium-long-term substitute risk for ResMed Inc. because obesity drugs can cut sleep apnea severity in some patients, but they do not replace PAP therapy for most users. Eli Lilly’s tirzepatide, approved by the U.S. FDA for moderate-to-severe obstructive sleep apnea in adults with obesity in 2024, showed about 27% AHI reduction and about 18% body-weight loss in trials.

• Not a broad direct substitute yet.
• Can shrink the addressable patient pool.
• Risk rises as obesity treatment scales.

For ResMed Inc., the threat is strongest in obese OSA patients who respond well to GLP-1 or dual-agonist therapy. Still, most patients need ongoing airway therapy, follow-up, or combination care, so substitution is partial, not full.

ResMed Inc.’s large base of connected devices and software keeps feeding recurring use, therapy data, and refill demand, so new entrants must beat an embedded ecosystem, not just a product. In FY2025, ResMed reported about $5.1 billion in revenue, showing how much of the market is already tied to its installed platform.

• Embedded workflows raise switching costs.
• Reimbursement ties favor incumbents.
• Customer data deepens lock-in.

Providers also avoid changing systems that already fit ordering, monitoring, and payer rules, which slows churn. That gives ResMed tighter customer control and makes entry much harder.

Digital health startups can enter niche monitoring and workflow software faster than hardware makers can enter regulated sleep and breathing markets. But scaling into ResMed Inc.’s platform needs interoperability, HIPAA-ready compliance, and clinician trust; ResMed reported about $5.1 billion in FY2025 revenue, showing the size of the moat.

So the threat of new entrants is moderate in software, but low in core devices. New apps can win small use cases, yet they still have to plug into provider systems and meet enterprise-grade security and support standards.

• Moderate threat in software
• Low threat in core devices
• Trust and compliance slow scale
• Integration raises switching costs